Searching for CRISPR 2.0, Intellia spends $45M cash on an unknown Berkeley spinout
Even as two of the first generation of CRISPR companies have shown powerful results in the clinic, they’ve faced a growing threat: new technologies such as base and prime editing that can conduct more versatile and potentially safer editing.
Intellia, which last year became the first company to show CRISPR can work directly in patients, is hoping that a little-known startup can help it stay on the cutting edge. On Thursday it announced a buyout of a tiny and effectively unknown Berkeley spinout called Rewrite Therapeutics for $45 million cash and $155 million in milestones that Intellia claims can do a host of genetic edits currently limited to prime editing and a couple other technologies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.